Tumour immunotherapies have been a breakthrough in clinical oncology but only a few patients benefit from this progress. Additional interventions that sensitize immunologically cold tumours for the administration of checkpoint modifiers are urgently needed. In this issue of EMBO Molecular Medicine, Aznar et al present the already approved yellow fever vaccine 17D as an oncolytic agent for tumour immunoactivation. In tumour-bearing mice, they demonstrated a convincing synergy of the vaccine with CD137 agonistic antibodies resulting in significantly improved survival.

中文翻译：

---

活疫苗——癌症病毒免疫疗法的捷径。


肿瘤免疫疗法已成为临床肿瘤学的突破，但只有少数患者从这一进展中受益。迫切需要采取额外的干预措施，使免疫冷肿瘤对检查点修饰剂的施用敏感。在本期《EMBO 分子医学》中，Aznar 等人介绍了已经批准的黄热病疫苗 17D，作为肿瘤免疫激活的溶瘤剂。在荷瘤小鼠中，他们证明了疫苗与 CD137 激动性抗体具有令人信服的协同作用，从而显着提高了生存率。